

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for production of virus or viral antigen, comprising the steps of (a) providing a culture of adherent cells bound to a microcarrier[[]]; (b) growing the cell culture to confluence[[]]; (c) infecting the cells with a virus; ~~and~~ (d) incubating said culture of cells infected with said virus to propagate said virus, wherein the cell density of the biomass of the cell culture grown to confluence is increased (i) prior to step (c) or (ii) after step (c) and wherein the cell density is maintained at high the increased cell density during step (d) as compared to the biomass grown to confluence during step (d), (b); and (e) harvesting the virus or viral antigen produced.

Claim 2 (currently amended): The method according to claim 1, wherein the density of the cell culture grown to confluence is ~~concentrated~~ increased at least about 1.3 fold.

Claim 3 (previously presented): The method according to claim 1, wherein the cell density of the cell culture grown to confluence is between about 0.6×10^6 and about 7.0×10^6 cells/ml.

Claim 4 (currently amended): The method according to claim 1, wherein the microcarrier is selected from the group consisting of microcarriers made of dextran, collagen, polystyrene, polyacrylamide, gelatine, glass, cellulose, polyethylene and plastic.

Claim 5 (previously presented): The method according to claim 1, wherein the microcarrier concentration in the culture of cells of step (a) is between about 0.5 g/l and about 14 g/l.

Claim 6 (currently amended): The method according to claim 1, wherein said cells are selected from the group consisting of adherent cells of VERO, BHK, CHO, RK, RK44, RK13, MRC-5, MDCK, CEF or diploid monolayer cells.

Claim 7 (previously presented): The method according to claim 1, wherein said cells bound to a microcarrier are grown in serum free medium.

Claim 8 (previously presented): The method according to claim 1, wherein said cells bound to a microcarrier are grown in serum and protein free medium.

Claim 9 (currently amended): The method according to claim 1, wherein the virus is selected from the group consisting of Influenza virus, Ross River Virus, Hepatitis A Virus, Vaccinia Virus and recombinant derivatives thereof, Herpes Simplex Virus, Japanese encephalitis Virus, West Nile Virus, Yellow Fever Virus and ~~chimerie~~ chimeras thereof, Rhinovirus and Reovirus.

Claim 10 (canceled).

Claim 11 (currently amended): A method for production of purified virus or virus antigen comprising the steps of:

- (a) providing a culture of adherent cells bound to a microcarrier;
- (b) growing the cell culture to confluence;
- (c) infecting the culture of cells with a virus;
- (d) incubating said culture of cells infected with said virus to propagate said virus;
- (e) harvesting the virus produced; and
- (f) purifying said virus harvested, wherein the cell density of the biomass of the

cell culture grown to confluence is increased

- (i) prior to step (c) or
- (ii) after step (c),

and wherein the cell culture is maintained at high the increased cell density during step (d) as compared to the biomass grown to confluence during step (d) (b).

Claim 12 (previously presented): The method according to claim 11, wherein the virus produced is harvested from the cell culture supernatant.

Claim 13 (previously presented): The method according to claim 11, wherein the virus produced is harvested from the cell biomass.

Claim 14 (currently amended): A method for production of Influenza virus, comprising the steps of:

- (a) providing a culture of adherent cells bound to a microcarrier;
- (b) growing the cell culture to confluence;
- (c) infecting the cells with an Influenza virus; ~~and~~
- (d) incubating said culture of cells infected with said Influenza virus to propagate

said virus, wherein the cell density of the biomass of the cell culture grown to confluence is increased

(i) prior to step (c) or

(ii) after step (c),

and wherein the cell culture is maintained at high the increased cell density during step (d) as compared to the biomass grown to confluence during step (d) (b); and
(e) harvesting said Influenza virus or Influenza virus antigen produced.

Claim 15 (previously presented): The method according to claim 14, wherein said cells are VERO cells.

Claim 16 (previously presented): The method according to claim 14, wherein said cells are MDCK cells.

Claim 17 (previously presented): The method according to claim 14, wherein said cells bound to a microcarrier are grown in serum free medium.

Claim 18 (previously presented): The method according to claim 14, wherein said cells bound to a microcarrier are grown in serum and protein free medium.

Claim 19 (currently amended): The method according to claim 14, wherein the cell culture grown to confluence is ~~concentrated~~ increased at least about 1.3 fold.

Claim 20 (canceled).

Claim 21 (previously presented): The method according to claim 14, further comprising the step (f) of purifying said Influenza virus harvested.

Claims 22-38 (canceled).